- Home
- NRGV vs CNTB Comparison
NRGV vs CNTB Comparison
Compare NRGV & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- CNTB
- Stock Information
- Founded
- NRGV 2017
- CNTB 2012
- Country
- NRGV United States
- CNTB United States
- Employees
- NRGV N/A
- CNTB N/A
- Industry
- NRGV Industrial Machinery/Components
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- CNTB Health Care
- Exchange
- NRGV Nasdaq
- CNTB Nasdaq
- Market Cap
- NRGV 133.4M
- CNTB 114.8M
- IPO Year
- NRGV N/A
- CNTB 2021
- Fundamental
- Price
- NRGV $3.07
- CNTB $1.61
- Analyst Decision
- NRGV Buy
- CNTB Strong Buy
- Analyst Count
- NRGV 3
- CNTB 2
- Target Price
- NRGV $1.58
- CNTB $7.50
- AVG Volume (30 Days)
- NRGV 2.7M
- CNTB 139.5K
- Earning Date
- NRGV 11-11-2025
- CNTB 09-05-2025
- Dividend Yield
- NRGV N/A
- CNTB N/A
- EPS Growth
- NRGV N/A
- CNTB N/A
- EPS
- NRGV N/A
- CNTB N/A
- Revenue
- NRGV $51,716,000.00
- CNTB $1,965,000.00
- Revenue This Year
- NRGV $314.58
- CNTB N/A
- Revenue Next Year
- NRGV $39.00
- CNTB N/A
- P/E Ratio
- NRGV N/A
- CNTB N/A
- Revenue Growth
- NRGV N/A
- CNTB N/A
- 52 Week Low
- NRGV $0.60
- CNTB $1.55
- 52 Week High
- NRGV $3.18
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- NRGV 80.91
- CNTB 42.74
- Support Level
- NRGV $2.11
- CNTB $1.55
- Resistance Level
- NRGV $3.18
- CNTB $1.65
- Average True Range (ATR)
- NRGV 0.23
- CNTB 0.16
- MACD
- NRGV 0.09
- CNTB -0.02
- Stochastic Oscillator
- NRGV 92.76
- CNTB 11.94
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.